PREOPERATIVE GONADOTROPINE-RELEASING HORMONE AGONIST THERAPY BEFORE SURGERY FOR UTERİN FIBROIDS

THE EFFICACY OF PREOPERATIVE USAGE OF GONADOTROPINE-RELEASING HORMONE AGONIST IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04192812

Enrollment

100

Registered

2019-12-10

Start date

2020-12-30

Completion date

2021-12-30

Last updated

2020-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gonadotropin-Releasing Hormone-Dependent Precocious Puberty, Uterine Fibroid

Brief summary

Uterin fibroids are the most common operation indication for hysterectomy. Dyring laparoscopic hysterectomy the amount of bleeding is a great difficulty.There are a lot of clinical researchs to reduce the haemorrhage during open hysterectomy but not laparoscopic procedure. In ALKU ERH clinic, researchers decided to smaller the size of fibroid by using GnRH analogues before total laparoscopic hysterectomy to reduce the haemorrhage amount.

Detailed description

After randomising patients to two groups, one of the group will be controle group and the other group will be working group and researchers decided to use 3,75 mg leuprolide acetate as GnRHa subcutanously in every four week, throughout 3 months before surgery to the working group, researchers will record intraoperative amount of bleeding by measuring the blood in suction scale, the duration of surgery, difference between preoperative haemoglobin levels and uterin weight. researchers will comparise all theese parameters ibn to two groups.

Interventions

DRUGPREOPERATİVE GnRHa THERAPY (LEUPROLIDE ACETATE) BEFORE SURGERY FOR UTERİN FIBROIDS

THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS

DRUGNO GnRHa

THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Intervention model description

PROSPECTİVE RANDOMİSED CONTROLLED TRİAL

Eligibility

Sex/Gender

FEMALE

Age

30 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* MYOMA UTERI * APPROPİATE FOR LAPAROSCOPY

Exclusion criteria

* MALİGNANCY

Design outcomes

Primary

Measure	Time frame	Description
AMOUNT OF BLEEDİNG	0 minute - 180 minute	WHOLE AMOUNT OF BLEEDING DURING SURGERY
DURATION AF SURGERY	0 MINUTE- 180 MINUTE	TIME BETWEEN INITIAL AND END OF SURGERY

Countries

Turkey (Türkiye)

Contacts

Primary ContactMERAL TUĞBA ÇİMŞİR

dr.tugbaacar@gmail.com05064742272

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026